.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AB02_Infliximab.Infliximab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AB02_Infliximab.Infliximab| name: | Infliximab |
| ATC code: | L04AB02 | route: | intravenous |
| n-compartments | 2 |
Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor alpha (TNF-α). It is used in the treatment of several autoimmune diseases, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Infliximab is approved and widely used today.
Pharmacokinetics in adult patients with rheumatoid arthritis, Crohn's disease, and other autoimmune diseases. Typical parameters are for adults (males and females) with standard IV dosing regimens.
Hemperly, A, & Vande Casteele, N (2018). Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clinical pharmacokinetics 57(8) 929–942. DOI:10.1007/s40262-017-0627-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29330783
Hanzel, J, et al., & Mathôt, RAA (2021). Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. Alimentary pharmacology & therapeutics 54(10) 1309–1319. DOI:10.1111/apt.16609 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34559426
Vande Casteele, N, et al., & Burns, JC (2018). Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease. Clinical pharmacokinetics 57(12) 1593–1601. DOI:10.1007/s40262-018-0653-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29623653